title: A review of new atypical antipsychotic launches in the United States.
abstract: In this article we investigate the post-launch retail prescription trends of asenapine (Saphris(®), Merck and Co.) and iloperidone (Fanapt(®), Vanda Pharmaceuticals Inc./Novartis), two new atypical antipsychotics to launch in the United States market in October 2009 and January 2010, respectively. In the first 12 months following the asenapine launch, and in the nine months since the iloperidone launch, asenapine and iloperidone have secured 0.22 and 0.10 percent of the total prescription market; however, both products nearly double those respective shares when total prescriptions are isolated to new patient prescriptions (0.44% for asenapine and 0.17% for iloperidone). Since launch, asenapine has shown stronger signs of growth, largely attributed to its approval in multiple indications as compared to iloperidone's single indication.
authors.affiliation: Mr. Ventimiglia is a Senior Analyst in Clinical Development Services, Quintiles, Inc., Durham, North Carolina.
authors.forename: Jeff
authors.initials: J
authors.lastname: Ventimiglia
authors.forename: Amir H
authors.initials: AH
authors.lastname: Kalali
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome